title: Preparation of antibodies against a novel immunosuppressant, FTY720, and development of an enzyme immunoassay for FTY720.
abstract: FTY720 (1) is a novel immunosuppressant (immunomodulator), derived from ISP-I (2: myriocin and thermozymocidin). To clarify the pharmacokinetic properties of 1, antibodies against 1 were prepared and a competitive enzyme immunoassay (EIA) was developed. Two kinds of haptens, 3 and 4, for 1 were synthesized and coupled to ovalbumin (OVA). Rabbits were immunized with 3-OVA or 4-OVA, and corresponding antibodies were obtained. Both antibodies recognized the 2-amino-2-(2-phenylethyl)propane-1,3-diol moiety in 1. Using the anti-3-OVA antibody, a competitive EIA for 1 was developed and evaluated. The range of quantification by the EIA was 0.06-10 ng/mL. The application of the EIA has enabled us to measure the FTY720 concentration in serum after oral administration of 1 (1mg/kg) to rats.
authors.affiliation: Faculty of Pharmaceutical Sciences, Setsunan University, Hirakata, Osaka 573-0101, Japan. Norimasa.Matsumoto@mitsui-sugar.co.jp
authors.forename: Norimasa
authors.initials: N
authors.lastname: Matsumoto
authors.forename: Takeyuki
authors.initials: T
authors.lastname: Kohno
authors.forename: Shuji
authors.initials: S
authors.lastname: Uchida
authors.forename: Takaaki
authors.initials: T
authors.lastname: Shimizu
authors.forename: Haruko
authors.initials: H
authors.lastname: Kusumoto
authors.forename: Ryoji
authors.initials: R
authors.lastname: Hirose
authors.forename: Kazuo
authors.initials: K
authors.lastname: Yanada
authors.forename: Wasako
authors.initials: W
authors.lastname: Kurio
authors.forename: Shoji
authors.initials: S
authors.lastname: Yamaguchi
authors.forename: Kazuhito
authors.initials: K
authors.lastname: Watabe
authors.forename: Tetsuro
authors.initials: T
authors.lastname: Fujita
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000906:Antibodies / Q000737:chemistry / Q000494:pharmacology*; D000937:Antigen-Antibody Reactions; D005260:Female; D000068876:Fingolimod Hydrochloride; D006241:Haptens / Q000737:chemistry; D007124:Immunoenzyme Techniques / Q000379:methods*; D015394:Molecular Structure; D010047:Ovalbumin / Q000737:chemistry; D011409:Propylene Glycols / Q000008:administration & dosage / Q000037:antagonists & inhibitors* / Q000737:chemistry*; D011817:Rabbits; D013110:Sphingosine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors / Q000737:chemistry; D013237:Stereoisomerism; D013329:Structure-Activity Relationship
chemical_list: D000906:Antibodies; D006241:Haptens; D011409:Propylene Glycols; D010047:Ovalbumin; D000068876:Fingolimod Hydrochloride; D013110:Sphingosine